Ascendis Pharma A/S
ASND · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $363,641 | $266,718 | $51,174 | $7,778 |
| % Growth | 36.3% | 421.2% | 557.9% | – |
| Cost of Goods Sold | $44,258 | $44,395 | $12,137 | $3,523 |
| Gross Profit | $319,383 | $222,323 | $39,037 | $4,255 |
| % Margin | 87.8% | 83.4% | 76.3% | 54.7% |
| R&D Expenses | $307,004 | $413,454 | $379,624 | $295,867 |
| G&A Expenses | $284,545 | $258,787 | $215,850 | $0 |
| SG&A Expenses | $284,545 | $258,787 | $215,850 | $160,180 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $6,597 | $5,623 | $5,377 | $0 |
| Operating Expenses | $598,146 | $677,864 | $600,851 | $456,047 |
| Operating Income | -$278,763 | -$455,541 | -$561,814 | -$451,792 |
| % Margin | -76.7% | -170.8% | -1,097.9% | -5,808.6% |
| Other Income/Exp. Net | -$94,478 | -$18,603 | -$16,003 | $67,848 |
| Pre-Tax Income | -$373,241 | -$474,144 | -$577,817 | -$383,944 |
| Tax Expense | $4,843 | $7,303 | $5,377 | -$367 |
| Net Income | -$378,084 | -$481,447 | -$583,194 | -$383,577 |
| % Margin | -104% | -180.5% | -1,139.6% | -4,931.6% |
| EPS | -6.53 | -8.55 | -10.4 | -7 |
| % Growth | 23.6% | 17.8% | -48.6% | – |
| EPS Diluted | -6.53 | -8.55 | -10.4 | -7 |
| Weighted Avg Shares Out | 57,892 | 56,287 | 56,072 | 54,772 |
| Weighted Avg Shares Out Dil | 57,892 | 56,287 | 56,072 | 54,772 |
| Supplemental Information | – | – | – | – |
| Interest Income | $14,361 | $16,857 | $7,426 | $692 |
| Interest Expense | $65,504 | $44,065 | $30,682 | $3,911 |
| Depreciation & Amortization | $17,714 | $18,911 | $17,514 | $15,391 |
| EBITDA | -$290,023 | -$411,168 | -$529,177 | -$364,642 |
| % Margin | -79.8% | -154.2% | -1,034.1% | -4,688.1% |